Skip to main content

Ipsen to acquire U.S.-based Epizyme for $247 million.

The primary focus of the acquisition is the lead medicine, Tazverik, which was granted FDA accelerated approval in 2020
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.